West Pharmaceutical Services Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.64B | $1.53B | $1.41B | $1.34B | $1.36B | $1.32B | $1.31B | $1.30B |
| Service | $495.1M | $477.7M | $462.4M | $456.9M | $458.7M | $446.8M | $448.9M | $438.4M |
| Product | $1.15B | $1.05B | $948.3M | $881.0M | $899.7M | $876.1M | $864.0M | $858.9M |
| Cost of Revenue | $1.17B | $1.09B | $1.01B | $944.0M | $973.6M | $933.7M | $878.7M | $853.0M |
| Gross Profit | $545.4M | $512.9M | $501.4M | $455.8M | $447.8M | $434.7M | $387.7M | $339.3M |
| Gross Margin | 33.2% | 33.5% | 35.5% | 34.1% | 33.0% | 32.9% | 29.5% | 26.2% |
| Operating Expenses | ||||||||
| Research & Development | $40.3M | $39.1M | $36.8M | $34.1M | $37.3M | $37.9M | $33.2M | $29.1M |
| SG&A Expense | $262.9M | $246.0M | $239.6M | $233.0M | $228.7M | $234.9M | $218.1M | $191.1M |
| Operating Income | $240.3M | $225.8M | $195.2M | $128.6M | $182.0M | $162.4M | $135.1M | $109.6M |
| Operating Margin | 14.6% | 14.7% | 13.8% | 9.6% | 13.4% | 12.3% | 10.3% | 8.4% |
| Interest Expense | $8.4M | $7.8M | $8.1M | $14.1M | $16.5M | $17.0M | $16.7M | $18.2M |
| Pretax Income | $240.7M | $222.4M | $189.8M | $116.1M | $169.0M | $147.1M | $108.6M | $92.7M |
| Income Tax Expense | $41.4M | $80.9M | $54.4M | $26.3M | $47.2M | $40.2M | $32.7M | $23.5M |
| Net Income | $206.9M | $150.7M | $143.6M | $95.6M | $127.1M | $112.3M | $80.7M | $75.5M |
| Net Margin | 12.6% | 9.8% | 10.2% | 7.1% | 9.4% | 8.5% | 6.1% | 5.8% |
| EPS (Basic) | $2.80 | $2.04 | $1.96 | $1.33 | $1.79 | $1.61 | $1.19 | $1.12 |
| EPS (Diluted) | $2.74 | $1.99 | $1.91 | $1.30 | $1.75 | $1.57 | $1.15 | $1.08 |
| Shares Outstanding (Basic) | 73.9M | 73.9M | 73.3M | 72.0M | 70.9M | 69.6M | 68.1M | 67.3M |
| Shares Outstanding (Diluted) | 75.4M | 75.8M | 75.0M | 73.8M | 72.8M | 71.4M | 71.8M | 74.0M |
| Dividends Per Share | $0.58 | $0.54 | $0.50 | $0.46 | $0.41 | $0.39 | $0.37 | $0.35 |